Overview

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Status:
Not yet recruiting
Trial end date:
2023-12-06
Target enrollment:
Participant gender:
Summary
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company